Status:

UNKNOWN

Rivaroxaban for Thromboprophylaxis in High-risk Cancer Patients With Totally Implantable Access Ports

Lead Sponsor:

LiuZhou People's Hospital

Conditions:

Rivaroxaban

Thromboprophylaxis

Eligibility:

All Genders

18-75 years

Phase:

PHASE3

Brief Summary

Rivaroxaban has been developed in the various clinical settings.Although cancer-associated DVT or PE was included in previously programs, limited patients of the total populations were cancer patients...

Eligibility Criteria

Inclusion

  • Eligibility Criteria:
  • Age 18-75 years;
  • Patients with malignant tumors who received implantable access ports for treatment;
  • Eastern Cooperative Oncology Group (ECOG) class 0-1;
  • will have a life expectancy \> 3 months;
  • Expected survival of more than 6 months;
  • Khorana score ≥2 point.
  • Exclusion Criteria:
  • Patients with a history of allergies to rivaroxaban;
  • History of recent major or clinically relevant bleeding within the previous 4 weeks.
  • Patients with bleeding risks: thrombocytopenia (platelet count \< 50\*109/L), clinically significant active bleeding, active gastric ulcer disease, severe arterial hypertension, history of previous stroke; Inadequate renal function; creatinine clearance \< 30 ml/min;
  • Inadequate hepatic function: aminotransferase \> 3 times the upper limit of normal (ULN) (if liver metastasis, alanine aminotransferase \> 5 times the ULN
  • Patients requiring strong cytochrome P450 3A4 (CYP3A4) inducers (rifampin, phenobarbital) or strong CYP3A4 inhibitors (HIV protease inhibitor, systemic ketoconazole) treatments.
  • Plan of treatment with bevacizumab or other anti-cancer drugs known to increase the bleeding risk.
  • Patients who have had anticoagulant drugs for any other reason.
  • Women who are pregnant or breastfeeding.

Exclusion

    Key Trial Info

    Start Date :

    March 8 2020

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    March 8 2022

    Estimated Enrollment :

    204 Patients enrolled

    Trial Details

    Trial ID

    NCT04309240

    Start Date

    March 8 2020

    End Date

    March 8 2022

    Last Update

    March 16 2020

    Active Locations (0)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 0 (0 locations)

    No Results Found

    We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.